Absence of IFN-γ accelerates thrombus resolution through enhanced MMP-9 and VEGF expression in mice

Journal of Clinical Investigation

Volumn 121, Issue 7, 2011, Pages 2911-2920

  Nosaka, Mizuho ^a   Ishida, Yuko ^a   Kimura, Akihiko ^a   Kuninaka, Yumi ^a   Inui, Masanori ^a   Mukaida, Naofumi ^b   Kondo, Toshikazu ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COLLAGEN; GAMMA INTERFERON; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 2 INHIBITOR; MATRIX METALLOPROTEINASE 9 INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GAMMA INTERFERON; PLASMINOGEN ACTIVATOR INHIBITOR; STAT1 PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFERIOR CAVA VEIN; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; RECANALIZATION; SIGNAL TRANSDUCTION; VEIN LIGATION;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE EXPRESSION; INTERFERON-GAMMA; LEUKOCYTES; MACROPHAGES, PERITONEAL; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TETRADECANOYLPHORBOL ACETATE; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTORS; VENA CAVA, INFERIOR;

EID: 79960015994     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI40782     Document Type: Article

References (53)

1. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med. 2004;351(3):268-277.
2. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167-1173. (Pubitemid 29155221)
3. Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med. 2001;1(1):7-26.
4. Coon WW, Willis PW 3rd, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation. 1973;48(4):839-846.
5. Anderson FA Jr, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933-938.
6. Peterson KL. Acute pulmonary thromboembolism: has its evolution been redefined? Circulation. 1999;99(10):1280-1283. (Pubitemid 29129910)
7. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther. 2002;300(3):729-735. (Pubitemid 34164973)
8. Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenicity. Thromb Haemost. 2007;97(5):722-729. (Pubitemid 46779957)
9. Wakefield TW, Henke PK. The role of inflammation in early and late venous thrombosis: Are there clinical implications? Semin Vasc Surg. 2005;18(3):118-129. (Pubitemid 41317196)
10. Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol. 2008;28(3):387-391.
11. Cines DB, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10):3527-3561. (Pubitemid 28225719)
12. Wakefield TW, et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15(2):258-268.
13. Stewart GJ. Neutrophils and deep venous thrombosis. Haemostasis. 1993;23(suppl 1):127-140. (Pubitemid 23116286)
14. Granger DN, Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol. 1994;55(5):662-675. (Pubitemid 24171735)
15. Tan P, Luscinskas FW, Homer-Vanniasinkam S. Cellular and molecular mechanisms of inflammation and thrombosis. Eur J Vasc Endovasc Surg. 1999;17(5):373-389. (Pubitemid 29213509)
16. Henke PK, et al. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. Arterioscler Thromb Vasc Biol. 2004;24(6):1130-1137.
17. Humphries J, McGuinness CL, Smith A, Waltham M, Poston R, Burnand KG. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. J Vasc Surg. 1999;30(5):894-899.
18. Henke PK, et al. Targeted deletion of CCR2 impairs deep vein thombosis resolution in a mouse model. J Immunol. 2006;177(5):3388-3397. (Pubitemid 44277859)
19. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol. 1993;11:571-611. (Pubitemid 23115018)
20. Hayashi T, Ishida Y, Kimura A, Iwakura Y, Mukaida N, Kondo T. IFN-γ protects cerulein-induced acute pancreatitis by repressing NF-κB activation. J Immunol. 2007;178(11):7385-7394. (Pubitemid 46847466)
21. Kimura A, et al. Interferon-γ plays protective roles in sodium arsenite-induced renal injury by up-regulating intrarenal multidrug resistance-associated protein 1 expression. Am J Pathol. 2006;169(4):1118-1128. (Pubitemid 351194350)
22. Ishida Y, et al. Essential involvement of IFN-γ in Clostridium difficile toxin A-induced enteritis. J Immunol. 2004;172(5):3018-3025. (Pubitemid 38263690)
23. Ishida Y, Kondo T, Takayasu T, Iwakura Y, Mukaida N. The essential involvement of cross-talk between IFN-γ and TGF-β in the skin wound-healing process. J Immunol. 2004;172(3):1848-1855. (Pubitemid 38116834)
24. Ishida Y, Kondo T, Ohshima T, Fujiwara H, Iwakura Y, Mukaida N. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J. 2002;16(10):1227-1236. (Pubitemid 34815410)
25. Tsuji H, et al. Alleviation of lipopolysaccharideinduced acute liver injury in Propionibacterium acnes-primed IFN-γ-deficient mice by a concomitant reduction of TNF-α, IL-12, and IL-18 production. J Immunol. 1999;162(2):1049-1055. (Pubitemid 29035433)
26. Tabrizi P, et al. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol. 1999;19(11):2801-2806. (Pubitemid 29536061)
27. Bugge TH, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A. 1996;93(12):5899-5904. (Pubitemid 26190774)
28. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood. 1998;91(6):2005-2009. (Pubitemid 28185501)
29. Modarai B, Burnand KG, Humphries J, Waltham M, Smith A. The role of neovascularisation in the resolution of venous thrombus. Thromb Haemost. 2005;93(5):801-809. (Pubitemid 40691533)
30. Wakefield TW, et al. Neovascularization during venous thrombosis organization: a preliminary study. J Vasc Surg. 1999;30(5):885-892.
31. Henke PK, et al. Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res. 2001;99(1):84-91.
32. Morishige K, et al. Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. Cardiovasc Res. 2003;57(2):572-585. (Pubitemid 36149754)
33. Varma MR, et al. Neutropenia impairs venous thrombosis resolution in the rat. J Vasc Surg. 2003;38(5):1090-1098. (Pubitemid 37409647)
34. Ali T, et al. Monocyte recruitment in venous thrombus resolution. J Vasc Surg. 2006;43(3):601-608. (Pubitemid 43332750)
35. Singh I, et al. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation. 2003;107(6):869-875. (Pubitemid 36241046)
36. Arnman V, Stemme S, Rymo L, Risberg B. Interferon-gamma modulates the fibrinolytic response in cultured human endothelial cells. Thromb Res. 1995;77(5):431-440.
37. Gyetko MR, Shollenberger SB, Sitrin RG. Urokinase expression in mononuclear phagocytes: cytokinespecific modulation by interferon-γ and tumor necrosis factor-α. J Leukoc Biol. 1992;51(3):256-263.
38. Gallicchio M, Hufnagl P, Wojta J, Tipping P. IFN-γ inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J Immunol. 1996;157(6):2610-2617. (Pubitemid 126450476)
39. Kosaka H, Yoshimoto T, Yoshimoto T, Fujimoto J, Nakanishi K. Interferon-γ is a therapeutic target molecule for prevention of postoperative adhesion formation. Nat Med. 2008;14(4):437-441. (Pubitemid 351499387)
40. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007;211(1):19-26. (Pubitemid 46363892)
41. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-γ and IFN-β: critical role of STAT-1α. J Immunol. 2001;167(9):5150-5159. (Pubitemid 33009751)
42. Ma Z, Chang MJ, Shah RC, Benveniste EN. Interferon-γ-activated STAT-1α suppresses MMP-9 gene transcription by sequestration of the coactivators CBP/p300. J Leukoc Biol. 2005;78(2):515-523.
43. Sato N, et al. Actions of TNF and IFN-γ on angiogenesis in vitro. J Invest Dermatol. 1990;95(6 suppl):85S-89S.
44. Maheshwari RK, Srikantan V, Bhartiya D, Kleinman HK, Grant DS. Differential effects of interferon gamma and alpha on in vitro model of angiogenesis. J Cell Physiol. 1991;146(1):164-169. (Pubitemid 21910037)
45. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827-839. (Pubitemid 36542523)
46. Whatling C, McPheat W, Hurt-Camejo E. Matrix management: assigning different roles for MMP-2 and MMP-9 in vascular remodeling. Arterioscler Thromb Vasc Biol. 2004;24(1):10-11. (Pubitemid 38082405)
47. Ducharme A, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106(1):55-62. (Pubitemid 30437240)
48. Modarai B, et al. Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution. Arterioscler Thromb Vasc Biol. 2008;28(10):1753-1759.
49. Waltham M, Burnand K, Fenske C, Modarai B, Humphries J, Smith A. Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution. J Vasc Surg. 2005;42(6):1183-1189. (Pubitemid 41817176)
50. Waltham M, Burnand KG, Collins M, Smith A. Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi. J Vasc Surg. 2000;32(5):988-996.
51. Kommineni VK, Nagineni CN, William A, Detrick B, Hooks JJ. IFN-γ acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. Biochem Biophys Res Commun. 2008;374(3):479-484.
52. Inui M, Ishida Y, Kimura A, Kuninaka Y, Mukaida N, Kondo T. Protective roles of CX3CR1-mediated signals in toxin A-induced enteritis through the induction of heme oxygenase-1 expression. J Immunol. 2011;186(1):423-431.
53. Ishida Y, et al. Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J Immunol. 2008;181(6):4208-4218.